Nektar Therapeutics Contract with Customer, Performance Obligation Satisfied in Previous Period
Nektar Therapeutics (NKTR) reported Contract with Customer, Performance Obligation Satisfied in Previous Period of $19.40 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-05.
Discontinued › Notes › Change in Contract with Customer, Asset and Liability
us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod · last filed 2021-11-05
- Nektar Therapeutics contract with customer, performance obligation satisfied in previous period for the quarter ending 2021-09-30 was $19.40M, a 14.54% decline year-over-year.
- Nektar Therapeutics contract with customer, performance obligation satisfied in previous period for the quarter ending 2021-06-30 was $20.50M, a 51.31% decline year-over-year.
- Nektar Therapeutics contract with customer, performance obligation satisfied in previous period for the quarter ending 2021-03-31 was $18.80M, a 57.85% decline year-over-year.
- Nektar Therapeutics contract with customer, performance obligation satisfied in previous period for the quarter ending 2020-12-31 was $20.20M, a 3.35% decline year-over-year.
- Nektar Therapeutics contract with customer, performance obligation satisfied in previous period for fiscal 2020 was $129.60M, a 67.23% increase from fiscal 2019.
- Nektar Therapeutics contract with customer, performance obligation satisfied in previous period for fiscal 2019 was $77.50M, a 18.68% decline from fiscal 2018.
- Nektar Therapeutics contract with customer, performance obligation satisfied in previous period for fiscal 2018 was $95.30M.
| Period end | Contract with Customer, Performance Obligation Satisfied in Previous Period 3 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 9 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 12 month |
|---|---|---|---|---|
| 2021-09-30 | $19.40M 10-Q · filed 2021-11-05 | $39.90M derived: sum of 2 quarters · filed 2021-11-05 | $58.70M 10-Q · filed 2021-11-05 | $78.90M derived: sum of 4 quarters · filed 2021-11-05 |
| 2021-06-30 | $20.50M 10-Q · filed 2021-08-06 | $39.30M 10-Q · filed 2021-08-06 | $59.50M derived: sum of 3 quarters · filed 2021-08-06 | $82.20M derived: sum of 4 quarters · filed 2021-11-05 |
| 2021-03-31 | $18.80M 10-Q · filed 2021-05-07 | $39.00M derived: sum of 2 quarters · filed 2021-05-07 | $61.70M derived: sum of 3 quarters · filed 2021-11-05 | $103.80M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-12-31 | $20.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $42.90M derived: sum of 2 quarters · filed 2021-11-05 | $85.00M derived: sum of 3 quarters · filed 2021-11-05 | $129.60M 10-K · filed 2021-02-26 |
| 2020-09-30 | $22.70M 10-Q · filed 2021-11-05 | $64.80M derived: sum of 2 quarters · filed 2021-11-05 | $109.40M 10-Q · filed 2021-11-05 | $130.30M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $42.10M 10-Q · filed 2021-08-06 | $86.70M 10-Q · filed 2021-08-06 | $107.60M derived: sum of 3 quarters · filed 2021-08-06 | $128.10M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $44.60M 10-Q · filed 2021-05-07 | $65.50M derived: sum of 2 quarters · filed 2021-05-07 | $86.00M derived: sum of 3 quarters · filed 2021-05-07 | $102.40M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $20.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $41.40M derived: sum of 2 quarters · filed 2021-02-26 | $57.80M derived: sum of 3 quarters · filed 2021-02-26 | $77.50M 10-K · filed 2021-02-26 |
| 2019-09-30 | $20.50M 10-Q · filed 2019-11-07 | $36.90M derived: sum of 2 quarters · filed 2019-11-07 | $56.60M 10-Q · filed 2019-11-07 | $87.60M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $16.40M 10-Q · filed 2019-08-09 | $36.10M 10-Q · filed 2019-08-09 | $67.10M derived: sum of 3 quarters · filed 2021-02-26 | $85.70M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $19.60M 10-Q · filed 2020-05-08 | $50.70M derived: sum of 2 quarters · filed 2021-02-26 | $69.30M derived: sum of 3 quarters · filed 2021-02-26 | $86.90M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $31.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $49.70M derived: sum of 2 quarters · filed 2021-02-26 | $67.30M derived: sum of 3 quarters · filed 2021-02-26 | $95.30M 10-K · filed 2021-02-26 |
| 2018-09-30 | $18.60M 10-Q · filed 2019-11-07 | $36.20M derived: sum of 2 quarters · filed 2019-11-07 | $64.20M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $17.60M 10-Q · filed 2019-08-09 | $45.60M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $28.00M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |